IO Biotech
IOBT
IOBT was delisted on the 6th of April, 2026.
21 hedge funds and large institutions have $3.59M invested in IO Biotech in 2025 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 14 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
12.58% less ownership
Funds ownership: 27.6% → 15.02% (-13%)
19% less funds holding
Funds holding: 26 → 21 (-5)
36% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 14
86% less capital invested
Capital invested by funds: $25.3M → $3.59M (-$21.7M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$2.63M |
| 2 |
Millennium Management
New York
|
+$2.4M |
| 3 |
BFM
Boothbay Fund Management
New York
|
+$1.02M |
| 4 |
Renaissance Technologies
New York
|
+$703K |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$431K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$8.58M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$2.74M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$1.81M |
| 4 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$1.45M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1.41M |
IOBT Hedge Fund Activity: Q3 2025 in Review
21 of the 7,631 institutional investors tracked by Wall St. Rank reported a position in IO Biotech (IOBT) for Q3 2025, worth a combined $3.59M — down 86% from $25.3M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of IOBT and 9 opened new positions — a net loss of 5 holders — while 5 trimmed existing stakes and 5 added.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $2.63M. The largest seller was Vivo Capital, exiting entirely with an estimated $8.58M sold.
- 21 institutional investors held IO Biotech (IOBT) as of Q3 2025, down from 26 in Q2 2025.
- Funds reported $3.59M of IO Biotech stock for Q3 2025, down 86% quarter-over-quarter.
- 9 funds opened new IO Biotech positions in Q3 2025 and 14 closed out, a net change of -5 holders.
- The largest IO Biotech buyer in Q3 2025 was Ikarian Capital, an estimated $2.63M added.
- The largest IO Biotech seller in Q3 2025 was Vivo Capital, an estimated $8.58M sold.
Based on aggregated 13F filings for Q3 2025.